Amarin: Any chance of a settlement before the appeal?

In Amarin’s pending Hatch-Waxman Vascepa case against Dr. Reddy’s and Hikma, we see at least obstacles to settlement at this time before resolution of the appeal: money, entry and invalidity.

Markman AdvisorsMay 1, 2020Amarin, Amarin Pharmaceuticals, $AMRN, Hatch-Waxman, Dr. Reddy's, Hikma, FTC, Actavis, Teva, Vascepa, settlement, REDUCE-IT, Protegrity, Marine Comments

Blog